Clinical trials: Epidermis
Breast Cancer
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal…
- Trial name
- NCT05304962
- Testing
- RGT-419B, RGT-419B in combination with hormonal therapy
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Regor Pharmaceuticals Inc.
Glioblastoma Multiforme, Glycolytic Index
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors.
- Conditions
- Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
- Trial name
- NCT06059690
- Testing
- pH Measurement of in vivo tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Ulcer of Lower Extremity
Plasma On Chronic Wounds for Epidermal Regeneration
Every year, 5 million people throughout Germany suffer from extensive, often chronic wounds. Cold plasma is an innovative therapeutic approach in the treatment of these persistent tissue defects.
- Trial name
- POWER (NCT05855499)
- Testing
- CPtcube, CPTpatch
- Where
- 8 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Coldplasmatech
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01394211
- Testing
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer.
- Trial name
- NCT00498992
- Testing
- collagen/aloe vera/vitamin E/lidocaine topical hydrogel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ingalls Memorial Hospital
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Type 1 Diabetes
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
The study is a two centre, open-label, uncontrolled single group phase 1A study of C19-A3 GNP peptide (10 μg peptide equivalent content) administered via Nanopass microneedles every 28 days for 8 weeks (3 doses), with follow-up…
- Trial name
- EE-ASI-1 (NCT02837094)
- Testing
- C19-A3 GNP
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Cardiff University
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up.
- Trial name
- NCT01934478
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Qingdao Central Hospital
Skin Rash
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
- Trial name
- NCT00709878
- Testing
- Skin Biopsy of Skin Rash Secondary to EGFRI Use
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
NSCLC Harboring EGFR Mutations
JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
This is a single-arm clinical study evaluating the safety, tolerability, and preliminary efficacy of JS212 in combination with JS111 as first-line treatment in participants with epidermal growth factor receptor (EGFR)-mutant…
- Trial name
- NCT07714304
- Testing
- JS212 for Injection, JS111 capsules (AP-L1898)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Huan Zhou
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with…
- Conditions
- PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
- Trial name
- ReDiscover-2 (NCT06982521)
- Testing
- Zovegalisib, Capivasertib, Fulvestrant
- Where
- 243 sites in United States, Argentina and 25 more
- Volunteers
- 540 people
- Sponsor
- Relay Therapeutics, Inc.
Epidermal Cyst
Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
The purpose of this trial is to compare two standard of care treatments for removing epidermal cysts. Surgical excision removes the entire cyst but requires a larger hole in the skin.
- Trial name
- NCT00165958
- Testing
- Excisional surgery of epidermal cyst, Punch incision of epidermal cyst
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the…
- Trial name
- NCT00567359
- Testing
- Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
This is a prospective, open label, interventional trial beginning with a phase 1b safety run-in followed by an expansion cohort.
- Trial name
- Osi+Ipi (NCT04141644)
- Testing
- Ipilimumab, Osimertinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
This study is a prospective, multicenter, single arm clinical study. Thirty subjects who will have been diagnosed with locally advanced or metastatic non-small cell lung cancer with EGFR 21L858R mutation detected in lung cancer…
- Trial name
- NCT06102928
- Testing
- Combined therapy of anlotinib and aumolertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Kunming Medical University
Colorectal Cancer
Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients
The study aims to explore the clinical utility of circulating tumour DNA (ctDNA) in assessing for alterations of anti-epidermal growth factor receptor (EGFR) primary resistance in RAS and BRAF wild-type metastatic colorectal…
- Trial name
- NCT05051592
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer, Pancreatic Cancer
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC).
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT02284139
- Testing
- Arm EGF ointment 1ppm, Arm EGF ointment 20 ppm
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Dong-A University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.